Missouri Judge Denies AG's Immediate Halt on 7-OH Kratom Sales by American Shaman, Signaling Ongoing Legal Battle

Missouri Judge Denies AG's Immediate Halt on 7-OH Kratom Sales by American Shaman, Signaling Ongoing Legal Battle

Missouri, May 8, 2026 – In a significant development for the kratom industry, a Jackson County judge has denied Missouri Attorney General Catherine Hanaway's request for a temporary restraining order that would have immediately halted the sale of 7-hydroxymitragynine (7-OH) kratom products by Kansas City-based CBD American Shaman and its affiliated companies. The ruling means American Shaman can continue selling these products for now, as the court will consider "other injunctive relief sought in the pleadings at a future hearing to consider the issues."

What Happened: Attorney General Hanaway, in collaboration with the Missouri Department of Health and Senior Services, had sought an immediate injunction, arguing that 7-OH products are "hazardous opioids" banned under state and federal law. The lawsuit, filed in Jackson County Circuit Court, accused American Shaman of violating the Missouri Merchandising Practices Act by selling unapproved drugs and adulterated food products, and engaging in deceptive marketing, including offering free samples of 7-OH. The Attorney General's office presented an FDA report labeling 7-OH as a "potent opioid that poses an emerging public health threat," alongside state health data linking synthetic 7-OH to Missouri deaths.

Conversely, American Shaman's owner, Vince Sanders, maintains the safety of their products, citing studies he funded and claiming that 7-OH products have contributed to a decline in traditional opioid-related deaths. The judge's decision to deny the immediate halt was based on "competing affidavits" from experts on both sides, indicating a need for further deliberation on the scientific and legal arguments.

Why It Matters to Kratom Merchants and Consumers: This ruling provides a temporary reprieve for American Shaman and, by extension, other kratom merchants in Missouri selling 7-OH products. It underscores the ongoing legal and regulatory uncertainty surrounding 7-OH, a compound found in small amounts in natural kratom but often present in higher, engineered concentrations in commercial products. For consumers, the decision means continued access to these products for the time being, but also highlights the contentious debate about their safety and regulatory status. The Missouri Department of Health and Senior Services warns that engineered 7-OH is "13 times stronger than morphine at affecting the body's opioid receptors" and can lead to addiction, poisoning, and death.

Compliance Implications: While the immediate halt was denied, the underlying lawsuit and ongoing legislative efforts in Missouri signal a clear trend towards stricter regulation of kratom, especially concerning 7-OH. Several proposed bills, such as Senate Bill 927 and House Bill 1595, aim to impose age restrictions (21 or 18), limit 7-OH content (e.g., 2% of alkaloid composition or 0.02% of total product weight), ban synthetic alkaloids, and mandate stringent labeling requirements. This legal skirmish serves as a critical reminder that the regulatory landscape for kratom is dynamic and can change rapidly.

What High-Risk Merchants Need to Know about COAs, Lab Testing, and Regulatory Compliance: For high-risk kratom merchants, proactive and rigorous compliance measures are no longer optional but essential for long-term viability. The core of this compliance lies in transparent and comprehensive lab testing and the provision of Certificates of Analysis (COAs).

1. Mandatory Lab Testing: All kratom products, particularly those containing 7-OH, must undergo thorough third-party lab testing. These tests should analyze:

   • Alkaloid Profile: Precisely quantify mitragynine and 7-hydroxymitragynine content. Be aware of proposed limits in various states (e.g., <0.4% 7-OH of alkaloid fraction in Utah, 0.02% of total product weight in North Carolina, and 2% of alkaloid composition in proposed Missouri legislation).
   • Contaminants: Screen for heavy metals (lead, arsenic, cadmium, mercury), and microbiological impurities (Salmonella, E. coli, yeast, mold).
   • Solvents: If extraction processes are used, test for residual chemicals.

2. Certificate of Analysis (COA) Transparency: A COA is the "report card" for your product and must be readily available to consumers. A legitimate COA should include:

   • Company name, product name, and a unique batch/lot number that matches the product.
   • Date of testing (should be recent, ideally within six months).
   • Name and address of the accredited third-party laboratory.
   • Specific testing methods used and clear results for all tested substances, including pass/fail grades against acceptable limits.

3. Third-Party and Accredited Labs: Always use independent, ISO/IEC 17025-accredited laboratories. This ensures unbiased, accurate results and adherence to rigorous testing protocols. In-house testing or COAs lacking clear lab credentials are red flags.

4. Batch-Specific Testing: Each batch of product must be tested individually, and the COA must correspond to that specific batch number to ensure accuracy and traceability.

The Missouri case underscores the critical need for high-risk kratom merchants to prioritize robust compliance programs, including comprehensive third-party lab testing and transparent COAs, to navigate the evolving regulatory landscape and build consumer trust.